XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue, Concentrations and Geographic Information (Tables)
9 Months Ended
Sep. 30, 2024
Revenue, Concentrations and Geographic Information  
Schedule of disaggregation of revenue by revenue type Effective the first quarter of 2024, the Company began reporting its services revenue in the following categories: BioLogistics Solutions and BioStorage/BioServices as Life Sciences Services, and its products revenue as Life Sciences Products. The Company believes this change better aligns its revenue categories with its strategic priorities. The following table disaggregates the Company’s revenue by such categories for the three and nine months ended September 30, 2024 and 2023 (in thousands):

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2024

    

2023

    

2024

    

2023

    

BioLogistics Solutions

$

35,302

$

32,486

$

103,076

$

97,093

BioStorage/BioServices

 

3,976

 

3,536

 

11,028

 

9,969

Life Sciences Services

39,278

36,022

114,104

107,062

Life Sciences Products

17,386

20,135

54,749

68,933

Total revenue

$

56,664

$

56,157

$

168,853

$

175,995

Schedule of geographical revenues, by origin The Company’s geographical revenues, by origin, for the three and nine months ended September 30, 2024 and 2023, were as follows (in thousands):

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2024

    

2023

    

2024

    

2023

    

Americas

$

30,772

$

31,570

$

93,799

$

96,351

Europe, the Middle East, and Africa (EMEA)

 

14,474

 

14,236

 

44,736

 

47,507

Asia Pacific (APAC)

 

11,418

 

10,351

 

30,318

 

32,137

Total revenue

$

56,664

$

56,157

$

168,853

$

175,995

Schedule of roll-forward of the allowance for credit losses

September 30, 

 

December 31,

    

2024

    

2023

Balance of allowance for credit losses, beginning of period

$

1,992

1,275

Change in expected credit losses

159

812

Write-offs, net of recoveries

 

(83)

(95)

Balance of allowance for credit losses, end of period

$

2,068

1,992